{
  "extraction_metadata": {
    "timestamp": "2025-10-01T13:39:22.666848",
    "source_type": "hta_submission",
    "indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
    "total_countries": 8,
    "temperature": 0.2
  },
  "outcomes_by_country": {
    "DE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "DE",
      "Outcomes": "progression-free survival (blinded independent central review), overall survival (time from randomisation to death from any cause), symptomatology (EORTC QLQ-C30), symptomatology (EORTC QLQ-LC13), health status (EORTC QLQ-C30), health status (EORTC QLQ-LC13), health status (EQ-5D visual analogue scale), health status (BPI-SF), health status (FACT-G GP5), health status (PGI-C), health-related quality of life (EORTC QLQ-C30), health-related quality of life (EORTC QLQ-LC13), health-related quality of life (BPI-SF), health-related quality of life (FACT-G GP5), health-related quality of life (PGI-C), adverse events (total), serious adverse events (SAEs), severe adverse events, discontinuation due to adverse events, interstitial lung disease (severe adverse event), liver disorders (severe adverse event), stomatitis (adverse event), peripheral oedema (adverse event), peripheral neuropathy (adverse event), alopecia (adverse event), blood and lymphatic system disorders (adverse event), fatigue (adverse event), fever (adverse event), infections and infestations (adverse event), side effects (PRO-CTCAE instrument)",
      "ChunksUsed": 25,
      "ContextTokens": 5955
    },
    "DK": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "DK",
      "Outcomes": "overall survival (OS), progression-free survival (PFS), progression-free survival (RECIST v1.1), event-free survival, time to progression (TTP), time to next treatment (TTNT), objective response rate (ORR), response rates, disease control rate, duration of response (DoR), time to response, treatment duration, adverse events, adverse events (CTCAE v5.0), adverse events (CTCAE v4.03), treatment discontinuation due to adverse events, grade 3 or higher adverse events, EORTC QLQ-C30, EORTC QLQ-LC13, EQ-5D-5L, NSCLC-SAQ, PGIS, PGIC, PRO-CTCAE, FACT-G (item GP5), changes in cancer-specific symptoms, changes in overall health status, quality-adjusted life years (QALYs), cost-effectiveness (incremental cost-effectiveness ratio, ICER)",
      "ChunksUsed": 25,
      "ContextTokens": 6659
    },
    "EN": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "EN",
      "Outcomes": "overall survival (OS), progression-free survival (PFS; RECIST 1.1), objective response rate (ORR; RECIST 1.1; blinded independent central review), complete response (RECIST 1.1), partial response (RECIST 1.1), health-related quality of life, visual analogue scale (progression-free health state), utility decrement per cycle of treatment, progression-free survival utility, health-state utility, quality-adjusted life years (QALYs), cost-effectiveness (incremental cost-effectiveness ratio, ICER), adverse events (general)",
      "ChunksUsed": 25,
      "ContextTokens": 5059
    },
    "FR": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "FR",
      "Outcomes": "progression-free survival (independent review panel, RECIST 1.1), progression-free survival (sensitivity analysis including new anti-cancer therapy initiation as event), objective response rate (independent review panel, RECIST 1.1), overall survival, duration of response (RECIST 1.1), disease control rate (complete, partial, or stable disease for at least 5 weeks), time to response (from treatment initiation to first complete or partial response), adverse events (general), serious adverse events, EORTC QLQ-C30, EORTC QLQ-LC13",
      "ChunksUsed": 25,
      "ContextTokens": 5534
    },
    "IT": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "IT",
      "Outcomes": "",
      "ChunksUsed": 6,
      "ContextTokens": 1644
    },
    "PO": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "PO",
      "Outcomes": "progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), overall survival (OS), diarrhoea, increased alanine aminotransferase (ALT), increased aspartate aminotransferase (AST), fatigue, fever, peripheral oedema, shortness of breath, cough, vomiting, decreased appetite, constipation, anaemia, increased asparaginase aminotransferase activity, increased alanine aminotransferase activity, alopecia, neutropenia, headache, abdominal pain, joint pain, back pain, oral cavity blockage, asthenia, weight loss, peripheral neuropathy, adverse events (general), serious adverse events (SAEs), treatment-related adverse events (general), treatment-related adverse events grade â‰¥ 3, treatment-related adverse events leading to discontinuation, treatment-related adverse events resulting in death, EORTC QLQ-C30, EORTC QLQ-LC13, quality-adjusted life years (QALYs), cost-effectiveness (incremental cost-utility ratio, ICUR), years of life gained (LYG)",
      "ChunksUsed": 25,
      "ContextTokens": 5936
    },
    "PT": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "PT",
      "Outcomes": "objective response rate (ORR), duration of response (DoR), disease control rate, time to progression, time to next treatment, overall survival (OS), progression-free survival (PFS; RECIST v1.1), eventless survival, duration of treatment, dropout rate, adverse events (general; CTCAE v5.0), grade 3-4 adverse event rate, serious adverse events, mortality-related toxicity, quality of life, overall health status, physical functioning, EORTC QLQ-C30, EORTC QLQ-LC13, EQ-5D-5L",
      "ChunksUsed": 25,
      "ContextTokens": 6420
    },
    "SE": {
      "Indication": "treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression, monotherapy context",
      "Country": "SE",
      "Outcomes": "progression-free survival (PFS), overall survival (OS), quality-adjusted life years (QALYs), cost-effectiveness (cost per QALY), health-related quality of life measured by time to death",
      "ChunksUsed": 25,
      "ContextTokens": 4940
    }
  }
}